Willingdon Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Willingdon Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$2K	Sell	20 -4	-17%	-$354	﹤0.01%	263
2019 Q4	$2K	Hold	24	–	–	﹤0.01%	337
2019 Q3	$2K	Buy	24 +4	+20%	+$332	﹤0.01%	371
2019 Q2	$2K	Sell	20 -4,805	-100%	-$410K	﹤0.01%	283
2019 Q1	$437K	Buy	4,825 +151	+3%	+$12.8K	0.11%	110
2018 Q4	$335K	Buy	4,674 +299	+7%	+$24.1K	0.1%	124
2018 Q3	$419K	Buy	4,375 +167	+4%	+$16.2K	0.11%	108
2018 Q2	$401K	Buy	4,208 +46	+1%	+$4.23K	0.12%	110
2018 Q1	$365K	Buy	4,162 +221	+6%	+$20.2K	0.12%	114
2017 Q4	$334K	Sell	3,941 -3,109	-44%	-$260K	0.11%	108
2017 Q3	$610K	Buy	7,050 +509	+8%	+$40.8K	0.22%	92
2017 Q2	$505K	Buy	6,541 +118	+2%	+$8.37K	0.2%	108
2017 Q1	$445K	Sell	6,423 -440	-6%	-$29.6K	0.18%	104
2016 Q4	$406K	Sell	6,863 -67	-1%	-$4.14K	0.19%	103
2016 Q3	$460K	Buy	6,930 +752	+12%	+$46.5K	0.23%	105
2016 Q2	$334K	Buy	+6,178	New	+$338K	0.17%	109

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return

Willingdon Wealth Management's XBI Position: Q1 2020 in Review

Willingdon Wealth Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 17% in Q1 2020, selling an estimated $354 and leaving 20 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Willingdon Wealth Management first reported a position in XBI in Q2 2016 and has held it in 16 quarters since. The position peaked at $610K in Q3 2017. 458 funds tracked by Wall St. Rank hold XBI as of Q1 2020.

Willingdon Wealth Management held 20 shares of State Street SPDR S&P Biotech ETF worth $2K as of Q1 2020.
Willingdon Wealth Management sold 4 State Street SPDR S&P Biotech ETF shares in Q1 2020, an estimated $354.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Willingdon Wealth Management's portfolio in Q1 2020, its #263 holding.
Willingdon Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2016 and has held it in 16 quarters since.
Willingdon Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $610K in Q3 2017.
458 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2020.

Based on Willingdon Wealth Management's 13F filing for Q1 2020, filed 21 Apr 2020.